Edwards Lifesciences Corporation $EW Position Reduced by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 538,041 shares of the medical research company’s stock after selling 13,007 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Edwards Lifesciences were worth $45,868,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after acquiring an additional 10,078 shares during the last quarter. Washington Trust Advisors Inc. boosted its stake in Edwards Lifesciences by 15.6% during the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after acquiring an additional 17,625 shares during the last quarter. Atlantic Union Bankshares Corp boosted its stake in Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after acquiring an additional 11,384 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares during the last quarter. Finally, Azzad Asset Management Inc. ADV boosted its stake in Edwards Lifesciences by 330.5% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock valued at $1,651,000 after acquiring an additional 16,296 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.3%

Shares of NYSE:EW opened at $83.24 on Friday. The stock has a market capitalization of $47.93 billion, a price-to-earnings ratio of 44.27, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $87.89. The company’s fifty day moving average is $81.41 and its two-hundred day moving average is $82.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter last year, the company earned $0.64 EPS. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 9,968 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $82.07, for a total value of $818,073.76. Following the sale, the vice president owned 22,798 shares of the company’s stock, valued at $1,871,031.86. This trade represents a 30.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares in the company, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 106,684 shares of company stock valued at $8,811,739 in the last quarter. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on EW shares. The Goldman Sachs Group reiterated a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Barclays reissued an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Finally, Robert W. Baird increased their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.65.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.